CollPlant Biotechnologies (ADR)
Produces plant-derived recombinant human collagen for bioinks, regenerative products, and aesthetics development.
Something off on this page? Send us feedback.
Profile
Produces plant-derived recombinant human collagen, bioinks, and regenerative-medicine materials, earning revenue from product sales, licensing, development milestones, and potential partner royalties while developing dermal fillers and regenerative breast implants.
Produces recombinant human collagen in genetically engineered tobacco plants, then sells the material and related bioinks to research laboratories, biotechnology and medical-device developers, and academic institutions. Collage and the BioFlex ready-to-print kit serve regenerative-medicine research, while VergenixSTR is marketed through distributors for tendinopathy treatment in parts of Europe. Research, manufacturing, headquarters, plant cultivation, and purification are concentrated in Israel.
Develops photocurable dermal fillers and bioprinted regenerative breast implants with strategic partners, alongside licensing and milestone-based development arrangements. The fillers and implants remained preclinical, and the earlier AbbVie filler collaboration has ended; prospective programs depend on clinical studies, regulatory authorization, partner resources, and access to cultivation and purification facilities.
Company facts
Categories
Key statistics
Analysts
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Feb 6, 2026 | D. Boral Capital | Downgrade | Buy | Hold |
Earnings
EPSReportedEstimate
RevenueReportedEstimate
Financials
Balance sheet, Mar 31, 2026Cash & short-term investments $4.3M · Total debt $2.6M · Total assets $9.2M · Shareholders' equity $4.9M
- Revenue
- $73.0K
- Operating income
- −$3.1M
- Net income
- −$3.1M
Dividends
No dividends on record.
Ownership
| Institutions1 holder · as of Mar 31, 2026 | 0.00% | 71 ADS | |
| Insiders4 holders · as of Apr 27, 2026 | 15.63% | 2.00M ADS | |
| Strategic holders1 holder · as of Feb 24, 2022 | 1.59% | 204.0K ADS | |
| Otherremainder | 82.78% | 10.60M ADS |
12.80M ADS as of Sep 1, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ami SagyInsider | 12.79% | 1.64M | 13Dfiled Nov 28, 2025 ↗ |
Hugh M. EvansInsiderdirector | 2.58% | 330,554 ordinary | Form 4filed Apr 27, 2026 ↗ |
The Upper Ground Tater TrustStrategic | 1.59% | 204,000 | 13G/Afiled Feb 24, 2022 ↗ |
Yehiel TalInsiderdirector, officer: Chief Executive Officer | 0.24% | 31,137 ordinary | Form 4filed Mar 19, 2026 ↗ |
Philippe BensimonInsiderofficer: VP Regulations and QA | 0.02% | 2,000 ordinary | Form 4filed Mar 18, 2026 ↗ |
| See all 12 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
Peers
- AbbVie
Juvéderm fillers and Natrelle implants span both key aesthetics programs.
- Establishment Labs
Motiva silicone implants compete for aesthetic breast-implant adoption.
- 3D Systems
Allevi bioprinting products overlap in bioink-enabled tissue engineering.
- Corning
Matrigel offers a benchmark extracellular matrix for 3D tissue research.
- Bio-Techne
Cultrex matrices and hydrogels compete in organoid and 3D cell culture.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CollPlant Biotechnologies (ADR) | $0.3281 | −15.44% | $5.0M | — | — | 12.9 | −96.5% |
| AbbVie | $256.45 | −0.00% | $452.97B | 72.2 | 16.9 | 7.0 | +10.2% |
| Establishment Labs | $69.38 | −1.79% | $2.04B | — | — | 8.3 | +31.7% |
| 3D Systems | $3.24 | −1.52% | $535.8M | — | — | 1.4 | −0.3% |
| Corning | $146.82 | −1.25% | $128.08B | 67.6 | 39.9 | 7.6 | +22.7% |
| Bio-Techne | $72.32 | −0.04% | $11.32B | 62.3 | 34.9 | 9.3 | +1.3% |
| Median | 67.6 | 34.9 | 7.6 | +10.2% |